Influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to antibodydependent cell-mediated cytotoxicity responses

Journal of Virology

Volumn 91, Issue 7, 2017, Pages

  Prévost, Jérémie ^a,b   Zoubchenok, Daria ^a,b   Richard, Jonathan ^a,b   Veillette, Maxime ^a,b   Pacheco, Beatriz ^a   Coutu, Mathieu ^a   Brassard, Nathalie ^a   Parsons, Matthew S ^c   Ruxrungtham, Kiat ^d,e   Bunupuradah, Torsak ^d   Tovanabutra, Sodsai ^k,l   Hwang, Kwan Ki ^f,j   Moody, Anthony ^f   Haynes, Barton F ^f   Bonsignori, Mattia ^f   Sodroski, Joseph ^g,h   Kaufmann, Daniel E ^a,b,i   Shaw, George M ^j   Chenine, Agnès L ^k,l   Finzi, Andrés ^a,b,m  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^l Henry Jackson Foundation for the Advancement of Military Medicine   (United States)

^m MCGILL UNIVERSITY   (Canada)

more..

Author keywords

ADCC; Env; Gp120; HIV 1; Phe 43 cavity; RV144

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HISTIDINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; MONOCLONAL ANTIBODY; SERINE; TRYPTOPHAN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS LOAD; AMINO ACID SEQUENCE; BINDING SITE; CONSENSUS SEQUENCE; HEK293 CELL LINE; HIV INFECTIONS; IMMUNOLOGY; PHYSIOLOGY; PROTEIN MOTIF; VIROLOGY;

AIDS VACCINES; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES; CONSENSUS SEQUENCE; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING;

EID: 85015233826     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02452-16     Document Type: Article

References (61)

1. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD, Sodroski J. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37:656-667. https://doi.org/10.1016/j.molcel.2010.02.012.
2. Helseth E, Olshevsky U, Furman C, Sodroski J. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65: 2119-2123.
3. Yang X, Mahony E, Holm GH, Kassa A, Sodroski J. 2003. Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology 313: 117-125. https://doi.org/10.1016/S0042-6822(03)00273-3.
4. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. https://doi.org/10.1038/31405.
5. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 107:1166-1171. https://doi.org/10.1073/pnas.0911004107.
6. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69:5723-5733.
7. Lu M, Blacklow SC, Kim PS. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075-1082. https://doi.org/10.1038/nsb1295-1075.
8. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430. https://doi.org/10.1038/387426a0.
9. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J. 2002. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76:9888-9899. https://doi.org/10.1128/JVI.76.19.9888-9899.2002.
10. Desormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, Gu C, Xiang SH, Mao Y, Sodroski J, Finzi A. 2013. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol 87:2549-2562. https://doi.org/10.1128/JVI.03104-12.
11. Finzi A, Pacheco B, Xiang SH, Pancera M, Herschhorn A, Wang L, Zeng X, Desormeaux A, Kwong PD, Sodroski J. 2012. Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J Virol 86:8974-8986. https://doi.org/10.1128/JVI.01076-12.
12. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. 2016. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113: E3413-E3422. https://doi.org/10.1073/pnas.1606636113.
13. Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibodydependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 89:545-551. https://doi.org/10.1128/JVI.02868-14.
14. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibodydependent cell-mediated cytotoxicity. J Virol 88:2633-2644. https://doi.org/10.1128/JVI.03230-13.
15. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT. 2014. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxic ity. Proc Natl Acad Sci U S A 111:6425-6430. https://doi.org/10.1073/pnas.1321507111.
16. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. 2014. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 88:6031-6046. https://doi.org/10.1128/JVI.00449-14.
17. von Bredow B, Arias JF, Heyer LN, Gardner MR, Farzan M, Rakasz EG, Evans DT. 12 August 2015. Envelope glycoprotein internalization protects human and simian immunodeficiency virus infected cells from antibody-dependent cell-mediated cytotoxicity. J Virol https://doi.org/10.1128/JVI.01911-15.
18. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schon A, Freire E, Routy JP, Smith AB, III, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A 112:E2687-E2694. https://doi.org/10.1073/pnas.1506755112.
19. Lee WS, Richard J, Lichtfuss M, Smith AB, III, Park J, Courter JR, Melillo BN, Sodroski JG, Kaufmann DE, Finzi A, Parsons MS, Kent SJ. 2015. Antibodydependent cellular cytotoxicity against reactivated HIV-1-infected cells. J Virol 90:2021-2030. https://doi.org/10.1128/JVI.02717-15.
20. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prevost J, Chapleau JP, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B, Martin L, Tremblay C, Hahn BH, Kaufmann DE, Wu X, Smith AB, III, Sodroski J, Pazgier M, Finzi A. 9 September 2016. Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anticluster A ADCC epitopes on HIV-1 envelope glycoproteins. EBioMedicine https://doi.org/10.1016/j.ebiom.2016.09.004.
21. Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. 2014. Flow cytometry-based assay to study HIV-1 gp120 specific antibodydependent cellular cytotoxicity responses. J Virol Methods 208:107-114. https://doi.org/10.1016/j.jviromet.2014.08.003.
22. Ding S, Veillette M, Coutu M, Prevost J, Scharf L, Bjorkman PJ, Ferrari G, Robinson JE, Sturzel C, Hahn BH, Sauter D, Kirchhoff F, Lewis GK, Pazgier M, Finzi A. 2016. A highly conserved residue of the HIV-1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anti-cluster A antibodies. J Virol 90:2127-2134. https://doi.org/10.1128/JVI.02779-15.
23. Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M. 2016. Paring down HIV Env: design and crystal structure of a stabilized inner domain of HIV-1 gp120 displaying a major ADCC target of the A32 region. Structure 24:697-709. https://doi.org/10.1016/j.str.2016.03.005.
24. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK. 2013. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 110:E69-E78. https://doi.org/10.1073/pnas.1217609110.
25. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85: 7029-7036. https://doi.org/10.1128/JVI.00171-11.
26. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, Devico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12.
27. Zoubchenok D, Veillette M, Prevost J, Sanders-Buell E, Wagh K, Korber B, Chenine AL, Finzi A. 7 December 2016. Histidine 375 modulates CD4 binding in HIV-1 CRF01_AE envelope glycoproteins. J Virol https://doi.org/10.1128/JVI.02151-16.
28. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. https://doi.org/10.1056/NEJMoa1113425.
29. McCutchan FE. 2006. Global epidemiology of HIV. J Med Virol 78(Suppl 1):S7-S12. https://doi.org/10.1002/jmv.20599.
30. Burke DS. 1997. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 3:253-259. https://doi.org/10.3201/eid0303.970301.
31. Taylor BS, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. N Engl J Med 359:1965-1966. https://doi.org/10.1056/NEJMc086373.
32. Hemelaar J. 2012. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 18:182-192. https://doi.org/10.1016/j.molmed.2011.12.001.
33. Hemelaar J. 2013. Implications of HIV diversity for the HIV-1 pandemic. J Infect 66:391-400. https://doi.org/10.1016/j.jinf.2012.10.026.
34. Veillette M, Coutu M, Richard J, Batraville LA, Desormeaux A, Roger M, Finzi A. 14 September 2014. Conformational evaluation of HIV-1 trimeric envelope glycoproteins using a cell-based ELISA assay. J Vis Exp https://doi.org/10.3791/51995.
35. Veillette M, Richard J, Pazgier M, Lewis GK, Parsons MS, Finzi A. 2016. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr HIV Res 14:9-23.
36. Schader SM, Colby-Germinario SP, Quashie PK, Oliveira M, Ibanescu RI, Moisi D, Mesplede T, Wainberg MA. 2012. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob Agents Chemother 56:4257-4267. https://doi.org/10.1128/AAC.00639-12.
37. + T cell killing mediated by antibodydependent cell-mediated cytotoxicity. EBioMedicine 3:122-134. https://doi.org/10.1016/j.ebiom.2015.12.004.
38. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38:176-186. https://doi.org/10.1016/j.immuni.2012.11.011.
39. Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, Mascola JR, Letvin NL. 2011. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 85:6906-6912. https://doi.org/10.1128/JVI.00326-11.
40. Banks ND, Kinsey N, Clements J, Hildreth JE. 2002. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18:1197-1205. https://doi.org/10.1089/08892220260387940.
41. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT. 2012. ADCC develops over time during persistent infection with liveattenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8:e1002890. https://doi.org/10.1371/journal.ppat.1002890.
42. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168-2173.
43. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. 1999. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 180:1338-1341. https://doi.org/10.1086/314988.
44. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyo EM, Wahren B, Rossi P, Jondal M. 1990. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 161:198-202. https://doi.org/10.1093/infdis/161.2.198.
45. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 58:127-131. https://doi.org/10.1097/QAI.0b013e31822c62b9.
46. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. 2012. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8:e1002739. https://doi.org/10.1371/journal.ppat.1002739.
47. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 9 May 2013. Vaccineinduced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A https://doi.org/10.1073/pnas.1301456110.
48. Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, Song Y, Du G, Gao R, Guo Y, Yan W, Xuan Y, Wei P. 16 June 2016. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retroviruses https://doi.org/10.1089/AID.2016.0029.
49. Zhong P, Pan Q, Ning Z, Xue Y, Gong J, Zhen X, Zhou L, Sheng F, Zhang W, Gai J, Cheng H, Yue Q, Xing H, Zhuang M, Lu W, Shao Y, Kang L. 2007. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23:847-856. https://doi.org/10.1089/aid.2006.0196.
50. He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, Xin R, Wei J, Feng Y, Hsi JH, Takebe Y, Shao Y, Group for HIV Molecular Epidemiology Survey. 2012. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One 7:e47289. https://doi.org/10.1371/journal.pone.0047289.
51. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, Subbarao S, Parekh BS, Srisuwanvilai L, Sutthent R, Wasi C, Heneine W, Choopanya K. 2001. Viral load differences in early infection with two HIV-1 subtypes. AIDS 15:683-691. https://doi.org/10.1097/00002030-200104130-00003.
52. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. 2007. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 21(Suppl 6):S39-S46. https://doi.org/10.1097/01.aids.0000299409.29528.23.
53. Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, Robb M, Beyrer C, Ruangyuttikarn C, Markowitz LE, Nelson KE. 2004. The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr 36:622-629. https://doi.org/10.1097/00126334-200405010-00011.
54. Robinson JE, Holton D, Elliott S, Ho DD. 1992. Distinct antigenic sites on HIV gp120 identified by a panel of human monoclonal antibodies. J Cell Biochem Suppl 16E:Q449.
55. Zhang W, Godillot AP, Wyatt R, Sodroski J, Chaiken I. 2001. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 40:1662-1670. https://doi.org/10.1021/bi001397m.
56. Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M, Montreal Primary HIV Infection and Long-Term Non-Progressor Study Groups. 2011. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood 117:145-155. https://doi.org/10.1182/blood-2010-08-301887.
57. Fontaine J, Coutlee F, Tremblay C, Routy JP, Poudrier J, Roger M, Montreal Primary HIV Infection and Long-Term Nonprogressor Study Groups. 2009. HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis 199:1007-1018. https://doi.org/10.1086/597278.
58. Peretz Y, Ndongala ML, Boulet S, Boulassel MR, Rouleau D, Cote P, Longpre D, Routy JP, Falutz J, Tremblay C, Tsoukas CM, Sekaly RP, Bernard NF. 2007. Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin Immunol 124:57-68. https://doi.org/10.1016/j.clim.2007.04.004.
59. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N, Canadian Cohort of HIV Infected Slow Progressors. 2011. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol 85:5949-5960. https://doi.org/10.1128/JVI.02652-10.
60. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. https://doi.org/10.1126/science.1195271.
61. Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K, HIV STAR Study Group. 2012. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 17:1351-1361. https://doi.org/10.3851/IMP2443.